Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H32N4O4.2Br |
Molecular Weight | 576.322 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Br-].[Br-].CN(CCCCCCN(C)C(=O)OC1=C[N+](C)=CC=C1)C(=O)OC2=C[N+](C)=CC=C2
InChI
InChIKey=GJHSNEVFXQVOHR-UHFFFAOYSA-L
InChI=1S/C22H32N4O4.2BrH/c1-23-13-9-11-19(17-23)29-21(27)25(3)15-7-5-6-8-16-26(4)22(28)30-20-12-10-14-24(2)18-20;;/h9-14,17-18H,5-8,15-16H2,1-4H3;2*1H/q+2;;/p-2
Molecular Formula | BrH |
Molecular Weight | 80.912 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C22H32N4O4 |
Molecular Weight | 416.5139 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.medicines.org.uk/emc/PIL.3897.latest.pdf | http://www.torii.co.jp/iyakuDB/data/if/if_ubr_t.pdf
Curator's Comment: description was created based on several sources, including:
http://www.medicines.org.uk/emc/PIL.3897.latest.pdf | http://www.torii.co.jp/iyakuDB/data/if/if_ubr_t.pdf
Distigmine is an acetylcholinesterase (AChE) inhibitor. Distigmine shows direct binding to muscarinic receptors in the rat bladder, and repeated oral administration of distigmine causes downregulation of muscarinic receptors in the rat bladder. The observed direct interaction of distigmine with the bladder muscarinic receptors may partly contribute to the therapeutic and/or side effects seen in the treatment of detrusor underactivity. It is usually used to treat myasthenia gravis, dysuria due to hypotonic bladder such as neurogenic bladder or after surgery. Common side effects are: nausea/vomiting, abdominal pain, diarrhea, increased salivation, hypersecretion in respiratory tract, sweating, bradycardia, miosis, difficulty in breathing. Distigmine has a greater risk of causing cholinergic crisis because of accumulation of the drug being more likely than with neostigmine or pyridostigmine and so distigmine is rarely used as a treatment for myasthenia gravis, unlike pyridostigmine and neostigmine.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL220 |
45.0 nM [IC50] | ||
Target ID: Muscarinic receptors (rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20410601 |
0.36 µM [Ki] | ||
Target ID: Nicotinic receptors (rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20410601 |
22.9 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Ubretid Approved UseIt is usually used to treat myasthenia gravis, dysuria due to hypotonic bladder such as neurogenic bladder or after surgery. |
|||
Primary | Ubretid Approved UseIt is usually used to treat myasthenia gravis, dysuria due to hypotonic bladder such as neurogenic bladder or after surgery. |
|||
Primary | Ubretid Approved UseIt is usually used to treat myasthenia gravis, dysuria due to hypotonic bladder such as neurogenic bladder or after surgery. |
PubMed
Title | Date | PubMed |
---|---|---|
Central and peripheral activity of cholinesterase inhibitors as revealed by yawning and fasciculation in rats. | 2001 Mar |
|
[Cholinergic crisis following administration of distigmine bromide: a case report]. | 2002 Jan |
|
Distigmine bromide induced acute psychotic disorder in a patient with multiple sclerosis. | 2003 Oct |
|
[A case of acute distigmine bromide intoxication in the therapeutic dosage for treatment of underactive neurogenic bladder]. | 2004 May |
|
[Distigmine bromide induced Parkinsonism. A case report]. | 2005 Aug |
|
Nocturnal hypersalivation caused by distigmine bromide in a patient with multiple system atrophy. | 2008 |
|
[Acute poisoning due to distigmine bromide]. | 2008 Apr |
|
[Three cases of cholinergic crisis in which serum distigmine bromide concentrations were measured]. | 2008 Jan |
|
Marked hydronephrosis and hydroureter after distigmine therapy in an adult male patient with paraplegia due to spinal cord injury: a case report. | 2009 Aug 6 |
|
Effect of distigmine bromide on the central cholinergic system. | 2009 Mar |
|
Pharmacokinetic and pharmacodynamic analysis of acetylcholinesterase inhibition by distigmine bromide in rats. | 2010 |
|
[Establishing indicators for diagnosis of cholinergic crisis]. | 2010 Oct |
Patents
Sample Use Guides
For dysuria due to hypotonic bladder such as neurogenic bladder or after surgery, for adults, take 1 tablet (5 mg of the active ingredient) daily.
For myasthenia gravis, for adults, take 1-4 tablet(s) (5-20 mg of the active ingredient) daily in 1-4 divided dose(s). Start with 1 tablet (5 mg) daily, and the dose should be adjusted according to symptoms.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20410601
Distigmine (30 nM—10 uM) inhibited specific [3H]oxotremorine-M binding in the bladder, submaxillary gland and cerebral cortex of rats in a concentration-dependent manner. The Ki values for distigmine did
not differ significantly among tissues.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:07:05 GMT 2023
by
admin
on
Fri Dec 15 15:07:05 GMT 2023
|
Record UNII |
750F36OP6J
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47792
Created by
admin on Fri Dec 15 15:07:05 GMT 2023 , Edited by admin on Fri Dec 15 15:07:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000081078
Created by
admin on Fri Dec 15 15:07:05 GMT 2023 , Edited by admin on Fri Dec 15 15:07:05 GMT 2023
|
PRIMARY | |||
|
15876-67-2
Created by
admin on Fri Dec 15 15:07:05 GMT 2023 , Edited by admin on Fri Dec 15 15:07:05 GMT 2023
|
PRIMARY | |||
|
764
Created by
admin on Fri Dec 15 15:07:05 GMT 2023 , Edited by admin on Fri Dec 15 15:07:05 GMT 2023
|
PRIMARY | |||
|
CHEMBL1199307
Created by
admin on Fri Dec 15 15:07:05 GMT 2023 , Edited by admin on Fri Dec 15 15:07:05 GMT 2023
|
PRIMARY | |||
|
m4675
Created by
admin on Fri Dec 15 15:07:05 GMT 2023 , Edited by admin on Fri Dec 15 15:07:05 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID60935985
Created by
admin on Fri Dec 15 15:07:05 GMT 2023 , Edited by admin on Fri Dec 15 15:07:05 GMT 2023
|
PRIMARY | |||
|
27522
Created by
admin on Fri Dec 15 15:07:05 GMT 2023 , Edited by admin on Fri Dec 15 15:07:05 GMT 2023
|
PRIMARY | |||
|
240-013-0
Created by
admin on Fri Dec 15 15:07:05 GMT 2023 , Edited by admin on Fri Dec 15 15:07:05 GMT 2023
|
PRIMARY | |||
|
750F36OP6J
Created by
admin on Fri Dec 15 15:07:05 GMT 2023 , Edited by admin on Fri Dec 15 15:07:05 GMT 2023
|
PRIMARY | |||
|
31512
Created by
admin on Fri Dec 15 15:07:05 GMT 2023 , Edited by admin on Fri Dec 15 15:07:05 GMT 2023
|
PRIMARY | |||
|
C87487
Created by
admin on Fri Dec 15 15:07:05 GMT 2023 , Edited by admin on Fri Dec 15 15:07:05 GMT 2023
|
PRIMARY | |||
|
SUB06323MIG
Created by
admin on Fri Dec 15 15:07:05 GMT 2023 , Edited by admin on Fri Dec 15 15:07:05 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |